Haloperidol Teva

Haloperidol Teva is a prescription medication that contains the active ingredient haloperidol, a butyrophenone antipsychotic. It is supplied in an unspecified strength and dosage form for intra‑articular, intramuscular, or intravenous administration. The product is marketed in the European Union and is used under medical supervision for several psychiatric conditions.

Haloperidol Teva is indicated for the management of several psychiatric disorders where dopamine blockade is therapeutic.

- Treatment of schizophrenia, including acute exacerbations. - Control of acute psychotic episodes unrelated to schizophrenia. - Management of manic episodes associated with bipolar disorder. - Reduction of motor and vocal tics in Tourette syndrome. - Adjunctive therapy for severe agitation in hospitalized patients. - Short‑term use for severe behavioral disturbances when rapid tranquilization is required.

Haloperidol Teva may cause a range of side effects that vary in frequency and severity.

Common: - Drowsiness or sedation. - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Dry mouth and increased salivation. - Constipation or gastrointestinal discomfort. - Blurred vision or other visual disturbances. - Weight gain or changes in appetite.

Serious: - Neuroleptic malignant syndrome, a potentially life‑threatening reaction. - Tardive dyskinesia, characterized by involuntary movements. - Severe hypotension or cardiovascular effects. - Elevated prolactin levels leading to hormonal disturbances. - Seizures in predisposed individuals. - Severe allergic reactions, including anaphylaxis.

Before initiating Haloperidol Teva, clinicians should evaluate patient history and monitor for specific risks.

- Assess for a history of cardiovascular disease, arrhythmias, or prolonged QT interval. - Evaluate for pre‑existing movement disorders or Parkinsonian symptoms. - Use caution in patients with hepatic or renal impairment; dose adjustments may be needed. - Monitor for signs of neuroleptic malignant syndrome, especially during dose escalation. - Consider pregnancy and lactation status; discuss potential risks with the patient. - Regularly review concomitant medications that may prolong the QT interval. - Educate patients about the importance of reporting new or worsening side effects promptly.

Haloperidol Teva can interact with several drug classes, affecting safety and efficacy.

Avoid: - Other dopamine antagonists or antipsychotics that increase the risk of extrapyramidal symptoms. - Medications known to prolong the QT interval, such as certain antiarrhythmics, macrolide antibiotics, and some antipsychotics. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may raise haloperidol plasma levels.

Use with caution: - CYP3A4 inducers (e.g., rifampin, carbamazepine) that could reduce therapeutic effect. - CNS depressants, including benzodiazepines and opioids, which may enhance sedation. - Anticholinergic agents that can mask extrapyramidal side effects. - Lithium, as combined use may increase the risk of neurotoxicity. - Alcohol, which can potentiate central nervous system effects.